Food Addiction and Obesity
The obesity epidemic in the US and abroad has increased interest in neurobiological mechanisms that contribute to eating in the absence of energy demand or hunger (overeating). Overeating, sometimes called 'hedonic' feeding because foods consumed are usually palatable and high in sugars and fats, is the leading cause of overweight and obesity in the US. One important factor that contributes to obesity is overeating triggered by sights, sounds, and smells (food cues) associated with palatable food (Stice et al, 2013; Tang et al, 2012) . For example, obese and overweight people report greater food craving and consume larger portions in response to food cues. A wealth of preclinical studies have demonstrated that these cue-triggered motivational responses are mediated by brain mesocorticolimbic circuits, particularly dopamine and glutamate transmission within the nucleus accumbens (NAc). In humans, the magnitude of activations in the NAc in response to food cues predicts future weight gain in normal-weight people and inability to lose weight after obesity onset. This suggests that differences in NAc function may mediate enhanced cue-triggered urges to eat in susceptible individuals both before and after weight gain. The overlap in the neural systems involved and similarities between responses to food, addictive drugs, and cues associated with them have sparked vibrant discussion about 'food addiction' (Carter et al, 2016) , despite some obvious differences between food and drug (eg, food does not have psychoactive properties in the pharmacological sense, nor is there a clear doseresponse relationship, etc.). So, can overeating that produces common obesity really be considered a form of addiction?
In a recent preclinical study we found that, prior to any diet manipulation, those rats that show the strongest motivational responses to a food cue subsequently gained the most weight when given free access to a fatty, sugary, 'junk-food' diet (Robinson et al, 2015) . Obesity-prone rats are also more sensitive to the locomotoractivating effects of cocaine, indicating enhanced responsivity of mesolimbic systems, and have greater excitability of medium spiny neurons in the NAc core prior to the development of obesity (Oginsky et al, 2016a, b) . Taken together, our data suggest that preexisting enhancements in NAc responsivity may render obesity-susceptible individuals more sensitive to the motivational properties of food cues. In addition, consumption of fatty, sugary foods alters NAc function in ways that also vary by susceptibility to obesity. For example, consumption of junk food enhances NAc glutamatergic transmission and produces an upregulation of calcium-permeable AMPA receptors (CP-AMPARs) in obesity-susceptible rats (Brown et al, 2015; Oginsky et al, 2016a) . Interestingly, increases in CPAMPARs were found prior to obesity onset, suggesting that they may drive enhanced motivational responses that promote weight gain (see Oginsky et al, 2016b for further discussion).
Enhanced cue triggered motivation and accompanying increases in NAc responsivity are thought to underlie drug addiction (Flagel et al, 2009) , and NAc CP-AMPARs mediate enhanced cue-trigged cocaine-seeking (Wolf, 2016). One pressing question that arises, however, is the extent to which the enhanced neurobehavioral responsivity found in obesitysusceptible rats is a form of aberrant motivation, akin to drug addiction. Brain reward circuits evolved in part to direct behavior towards food. Thus, enhancements in NAc responsivity and cue-triggered motivation could be described as an improved function of this system (ie, rendering individuals better able to find food) rather than dysfunction. Of course, not being able to curb cue-triggered urges in the current calorie-dense food environment is unhealthy, and it is not entirely clear where this idea leaves obesity-resistant individuals. Are they the outliers? However, to develop better prevention strategies for obesity it will be important to differentiate 'normal' neurobehavioral responses from fundamentally aberrant ones and to continue to challenge ourselves by asking these questions.
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In prevailing models of AD amyloidogenesis, Aβ's propensity to oligomerize and generate β-amyloid is viewed as an intrinsically abnormal and exclusively pathological activity. However, recent findings suggest Aβ oligomerization may help protect the brain from infection. Aβ shows potent in vitro microbicidal activities against human pathogens, consistent with identity as an antimicrobial peptide (Soscia et al, 2010) . Aβ expression also significantly increases survival of transgenic mice in acute encephalitis models (Kumar et al, 2016) . Moreover, fibrillization appears to mediate the protective activities of Aβ in brain and leads to the concentration and entrapment of pathogens within β-amyloid deposits (Kumar et al., 2016) . Confirmation of a physiological role for β-amyloid generation would shift the modality of Aβ's pathophysiology from abnormal stochastic behavior toward dysregulated innate immune response. This suggests a response to perceived immunochallenge may mediate AD amyloidosis. This may involve sterile inflammatory stimuli, as with aseptic inflammation diseases. Or alternatively, AD amyloidosis may be driven by subclinical chronic cerebral infection. It remains unclear if infection precedes the establishment of the amyloid cascade in AD brain. Aβ oligomer pathways and potential targets for therapeutic intervention. Recent studies of 'resilient' brains with high senile plaque loads have shown β-amyloid alone is insufficient for AD neurodegeneration. Neurofibrillary Tangles (NFTs) and neuroinflammation are also required. Shown are oligomer-mediated pathways contributing to neurodegeneration in AD and potential points for intervention (X). Possible approaches emerging from the antimicrobial peptide role of Aβ are indicated (??) as well as established therapeutic strategies, including secretase modulators that reduce the 42 amino acid Aβ isoforms (eg, GSM, NS-GSI, BSI), copper chelators (eg, PBT2), Aβ oligomerization blockers (eg, PBT2, ELND005, NRM8499), immunotherapies aimed at antibodymediated clearance of Aβ (eg, Bapi, Sola), antioxidants that attenuate ROS-mediated inflammation (eg, vitamin E, epigallo-catechine gallate, resveratrol), agents purported to be neuroprotective (eg, dimebon), and drugs that inhibit tau aggregation and NTF generation (eg, rhodanine-based and Phenylthiazolyl-hydrazide inhibitors).
